

Adult Malignant Glioma Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/A243C0255051EN.html>

Date: April 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: A243C0255051EN

Abstracts

Glioma is a broad category of brain and spinal cord tumors that come from glial cells brain cells that support nerve cells. The symptoms, prognosis, and treatment of a glioma depend on the person's age, the exact type of tumor, and the location of the tumor within the brain.

This report contains market size and forecasts of Adult Malignant Glioma Therapeutics in Global, including the following market information:

Global Adult Malignant Glioma Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Adult Malignant Glioma Therapeutics market was valued at 1329.5 million in 2021 and is projected to reach US\$ 1867.9 million by 2028, at a CAGR of 5.0% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Glioblastoma Multiforme Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Adult Malignant Glioma Therapeutics include Merck, Hoffmann-La Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceutical and Teva Pharmaceutical, etc. In 2021, the global top five

players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adult Malignant Glioma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Adult Malignant Glioma Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Type, 2021 (%)

Glioblastoma Multiforme

Anaplastic Astrocytoma

Anaplastic Oligodendroglioma

Other

Global Adult Malignant Glioma Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Specialty Clinics

Cancer and Radiation Therapy Centers

Others

Global Adult Malignant Glioma Therapeutics Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Adult Malignant Glioma Therapeutics Market Segment Percentages, By Region
and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Adult Malignant Glioma Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Adult Malignant Glioma Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Merck

Hoffmann-La Roche

Arbor Pharmaceuticals

Pfizer

AbbVie

Amgen

Bristol-Myers Squibb

Sun Pharmaceutical

Teva Pharmaceutical

Novocure

Eli Lilly

AstraZeneca

Novartis AG

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Adult Malignant Glioma Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Adult Malignant Glioma Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Adult Malignant Glioma Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Adult Malignant Glioma Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Adult Malignant Glioma Therapeutics Players in Global Market
- 3.2 Top Global Adult Malignant Glioma Therapeutics Companies Ranked by Revenue
- 3.3 Global Adult Malignant Glioma Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Adult Malignant Glioma Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Adult Malignant Glioma Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Players in Global Market
 - 3.6.1 List of Global Tier 1 Adult Malignant Glioma Therapeutics Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Adult Malignant Glioma Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Glioblastoma Multiforme

4.1.3 Anaplastic Astrocytoma

4.1.4 Anaplastic Oligodendroglioma

4.1.5 Other

4.2 By Type - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Adult Malignant Glioma Therapeutics Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Specialty Clinics

5.1.4 Cancer and Radiation Therapy Centers

5.1.5 Others

5.2 By Application - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Adult Malignant Glioma Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Adult Malignant Glioma Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Adult Malignant Glioma Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Adult Malignant Glioma Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Adult Malignant Glioma Therapeutics Revenue, 2017-2028

6.3.2 US Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.3.3 Canada Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.3.4 Mexico Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Adult Malignant Glioma Therapeutics Revenue, 2017-2028

6.4.2 Germany Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.3 France Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.4 U.K. Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.5 Italy Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.6 Russia Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.4.8 Benelux Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Adult Malignant Glioma Therapeutics Revenue, 2017-2028

6.5.2 China Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.5.3 Japan Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.5.4 South Korea Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.5.6 India Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Adult Malignant Glioma Therapeutics Revenue, 2017-2028

6.6.2 Brazil Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.6.3 Argentina Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, 2017-2028

6.7.2 Turkey Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.7.3 Israel Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Adult Malignant Glioma Therapeutics Market Size, 2017-2028

6.7.5 UAE Adult Malignant Glioma Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Merck

7.1.1 Merck Corporate Summary

7.1.2 Merck Business Overview

7.1.3 Merck Adult Malignant Glioma Therapeutics Major Product Offerings

7.1.4 Merck Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)

7.1.5 Merck Key News

7.2 Hoffmann-La Roche

7.2.1 Hoffmann-La Roche Corporate Summary

7.2.2 Hoffmann-La Roche Business Overview

7.2.3 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Major Product Offerings

7.2.4 Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)

7.2.5 Hoffmann-La Roche Key News

7.3 Arbor Pharmaceuticals

7.3.1 Arbor Pharmaceuticals Corporate Summary

7.3.2 Arbor Pharmaceuticals Business Overview

7.3.3 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Major Product Offerings

7.3.4 Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)

7.3.5 Arbor Pharmaceuticals Key News

7.4 Pfizer

7.4.1 Pfizer Corporate Summary

7.4.2 Pfizer Business Overview

7.4.3 Pfizer Adult Malignant Glioma Therapeutics Major Product Offerings

7.4.4 Pfizer Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)

7.4.5 Pfizer Key News

7.5 AbbVie

7.5.1 AbbVie Corporate Summary

7.5.2 AbbVie Business Overview

7.5.3 AbbVie Adult Malignant Glioma Therapeutics Major Product Offerings

7.5.4 AbbVie Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)

7.5.5 AbbVie Key News

7.6 Amgen

7.6.1 Amgen Corporate Summary

- 7.6.2 Amgen Business Overview
- 7.6.3 Amgen Adult Malignant Glioma Therapeutics Major Product Offerings
- 7.6.4 Amgen Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
- 7.6.5 Amgen Key News
- 7.7 Bristol-Myers Squibb
 - 7.7.1 Bristol-Myers Squibb Corporate Summary
 - 7.7.2 Bristol-Myers Squibb Business Overview
 - 7.7.3 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.7.4 Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.7.5 Bristol-Myers Squibb Key News
- 7.8 Sun Pharmaceutical
 - 7.8.1 Sun Pharmaceutical Corporate Summary
 - 7.8.2 Sun Pharmaceutical Business Overview
 - 7.8.3 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.8.4 Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.8.5 Sun Pharmaceutical Key News
- 7.9 Teva Pharmaceutical
 - 7.9.1 Teva Pharmaceutical Corporate Summary
 - 7.9.2 Teva Pharmaceutical Business Overview
 - 7.9.3 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.9.4 Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.9.5 Teva Pharmaceutical Key News
- 7.10 Novocure
 - 7.10.1 Novocure Corporate Summary
 - 7.10.2 Novocure Business Overview
 - 7.10.3 Novocure Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.10.4 Novocure Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.10.5 Novocure Key News
- 7.11 Eli Lilly
 - 7.11.1 Eli Lilly Corporate Summary
 - 7.11.2 Eli Lilly Business Overview

- 7.11.3 Eli Lilly Adult Malignant Glioma Therapeutics Major Product Offerings
- 7.11.4 Eli Lilly Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
- 7.11.5 Eli Lilly Key News
- 7.12 AstraZeneca
 - 7.12.1 AstraZeneca Corporate Summary
 - 7.12.2 AstraZeneca Business Overview
 - 7.12.3 AstraZeneca Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.12.4 AstraZeneca Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.12.5 AstraZeneca Key News
- 7.13 Novartis AG
 - 7.13.1 Novartis AG Corporate Summary
 - 7.13.2 Novartis AG Business Overview
 - 7.13.3 Novartis AG Adult Malignant Glioma Therapeutics Major Product Offerings
 - 7.13.4 Novartis AG Adult Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
 - 7.13.5 Novartis AG Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Adult Malignant Glioma Therapeutics Market Opportunities & Trends in Global Market
- Table 2. Adult Malignant Glioma Therapeutics Market Drivers in Global Market
- Table 3. Adult Malignant Glioma Therapeutics Market Restraints in Global Market
- Table 4. Key Players of Adult Malignant Glioma Therapeutics in Global Market
- Table 5. Top Adult Malignant Glioma Therapeutics Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Adult Malignant Glioma Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Adult Malignant Glioma Therapeutics Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Adult Malignant Glioma Therapeutics Product Type
- Table 9. List of Global Tier 1 Adult Malignant Glioma Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Adult Malignant Glioma Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Adult Malignant Glioma Therapeutics Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Adult Malignant Glioma Therapeutics Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Adult Malignant Glioma Therapeutics Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Adult Malignant Glioma Therapeutics Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Adult Malignant Glioma Therapeutics Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. Merck Corporate Summary

Table 31. Merck Adult Malignant Glioma Therapeutics Product Offerings

Table 32. Merck Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Hoffmann-La Roche Corporate Summary

Table 34. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Product Offerings

Table 35. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Arbor Pharmaceuticals Corporate Summary

Table 37. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Product Offerings

Table 38. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer Adult Malignant Glioma Therapeutics Product Offerings

Table 41. Pfizer Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. AbbVie Corporate Summary

Table 43. AbbVie Adult Malignant Glioma Therapeutics Product Offerings

Table 44. AbbVie Adult Malignant Glioma Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Amgen Corporate Summary

Table 46. Amgen Adult Malignant Glioma Therapeutics Product Offerings

Table 47. Amgen Adult Malignant Glioma Therapeutics Revenue (US\$, Mn),
(2017-2022)

Table 48. Bristol-Myers Squibb Corporate Summary

Table 49. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Product Offerings

Table 50. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue (US\$,
Mn), (2017-2022)

Table 51. Sun Pharmaceutical Corporate Summary

Table 52. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Product Offerings

Table 53. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US\$,
Mn), (2017-2022)

Table 54. Teva Pharmaceutical Corporate Summary

Table 55. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Product Offerings

Table 56. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue (US\$,
Mn), (2017-2022)

Table 57. Novocure Corporate Summary

Table 58. Novocure Adult Malignant Glioma Therapeutics Product Offerings

Table 59. Novocure Adult Malignant Glioma Therapeutics Revenue (US\$, Mn),
(2017-2022)

Table 60. Eli Lilly Corporate Summary

Table 61. Eli Lilly Adult Malignant Glioma Therapeutics Product Offerings

Table 62. Eli Lilly Adult Malignant Glioma Therapeutics Revenue (US\$, Mn),
(2017-2022)

Table 63. AstraZeneca Corporate Summary

Table 64. AstraZeneca Adult Malignant Glioma Therapeutics Product Offerings

Table 65. AstraZeneca Adult Malignant Glioma Therapeutics Revenue (US\$, Mn),
(2017-2022)

Table 66. Novartis AG Corporate Summary

Table 67. Novartis AG Adult Malignant Glioma Therapeutics Product Offerings

Table 68. Novartis AG Adult Malignant Glioma Therapeutics Revenue (US\$, Mn),
(2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Adult Malignant Glioma Therapeutics Segment by Type in 2021

Figure 2. Adult Malignant Glioma Therapeutics Segment by Application in 2021

Figure 3. Global Adult Malignant Glioma Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Adult Malignant Glioma Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Adult Malignant Glioma Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Adult Malignant Glioma Therapeutics Revenue in 2021

Figure 8. By Type - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Adult Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Adult Malignant Glioma Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. Merck Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Hoffmann-La Roche Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Arbor Pharmaceuticals Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. AbbVie Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Amgen Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Bristol-Myers Squibb Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Sun Pharmaceutical Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Teva Pharmaceutical Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Novocure Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Eli Lilly Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. AstraZeneca Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Novartis AG Adult Malignant Glioma Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Adult Malignant Glioma Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/A243C0255051EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A243C0255051EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970